Javascript must be enabled to continue!
Therapeutic Potential Of M@B 40 (M = Mg and Ca) Fullerene as a Drug Delivery System for Gemcitabine Anti‐Lung Cancer Drug: A DFT Approach
View through CrossRef
Abstract
In this research work, we employed density functional theory (DFT) calculations both in gas and aqueous environment to examine the gemcitabine drug delivery efficacy of M@B
40
(M = Mg and Ca) fullerene. The outcomes revealed that gemcitabine tends to bind through its double bonded O group to the boron atom of Mg@B
40
and Ca@B
40
fullerenes, resulting with significant adsorption energies. QTAIM analysis is utilized to clarify the interaction between the fullerene and gemcitabine complex, uncovering the existence of partial covalent interactions. The NBO and MEP analyses provides additional support for the interaction and significant charge transfer occurring between the gemcitabine drug and M@B
40
(M = Mg and Ca) fullerene. The drug loading capacity of both metal‐encapsulated B
40
fullerene is high, as they can accommodate up to five gemcitabine drug molecules. The drug release process and recovery time calculations are also conducted to facilitate the rapid desorption of the drug from the carrier. These findings offer valuable insights into the potential applications of M@B
40
(M = Mg and Ca) fullerene in the realm of drug delivery within the biological systems.
Title: Therapeutic Potential Of M@B
40
(M = Mg and Ca) Fullerene as a Drug Delivery System for Gemcitabine Anti‐Lung Cancer Drug: A DFT Approach
Description:
Abstract
In this research work, we employed density functional theory (DFT) calculations both in gas and aqueous environment to examine the gemcitabine drug delivery efficacy of M@B
40
(M = Mg and Ca) fullerene.
The outcomes revealed that gemcitabine tends to bind through its double bonded O group to the boron atom of Mg@B
40
and Ca@B
40
fullerenes, resulting with significant adsorption energies.
QTAIM analysis is utilized to clarify the interaction between the fullerene and gemcitabine complex, uncovering the existence of partial covalent interactions.
The NBO and MEP analyses provides additional support for the interaction and significant charge transfer occurring between the gemcitabine drug and M@B
40
(M = Mg and Ca) fullerene.
The drug loading capacity of both metal‐encapsulated B
40
fullerene is high, as they can accommodate up to five gemcitabine drug molecules.
The drug release process and recovery time calculations are also conducted to facilitate the rapid desorption of the drug from the carrier.
These findings offer valuable insights into the potential applications of M@B
40
(M = Mg and Ca) fullerene in the realm of drug delivery within the biological systems.
Related Results
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Comparison of Efficacy and Toxicity of Gemcitabine-Cisplatin Regimen VS Gemcitabine-Capecitabine Regimen as First Line Chemotherapy in Advanced Gallbladder Carcinoma
Comparison of Efficacy and Toxicity of Gemcitabine-Cisplatin Regimen VS Gemcitabine-Capecitabine Regimen as First Line Chemotherapy in Advanced Gallbladder Carcinoma
Introduction: Gallbladder cancer (GBC) is the commonest malignancy of the biliary tract, and majority of patients with GBC in India has advanced unresectable disease. This study wa...
Abstract 1658: Gemcitabine impacts expression of antigen presentation proteins by pancreatic cancer cells
Abstract 1658: Gemcitabine impacts expression of antigen presentation proteins by pancreatic cancer cells
Abstract
Background: Pancreatic adenocarcinoma is one of the deadliest type of cancers with a 5-year overall survival rate of 10%. A standard chemotherapy approach f...
Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells
Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells
Gemcitabine is a chemotherapeutic used clinically to treat a variety of cancers. However, because it lacks tumor cell specificity, gemcitabine may cause off-target cytotoxicity and...
Abstract 1427: Investigating role of RECQ1 in response to gemcitabine treatment in triple negative breast cancer
Abstract 1427: Investigating role of RECQ1 in response to gemcitabine treatment in triple negative breast cancer
Abstract
The response of cancer cells to therapeutic drugs aimed at causing DNA damage is dependent on proteins that play roles in DNA repair. Single nucleotide poly...
Improved In Vitro Anti-Tumoral Activity, Intracellular Uptake and Apoptotic Induction of Gemcitabine-Loaded Pegylated Unilamellar Liposomes
Improved In Vitro Anti-Tumoral Activity, Intracellular Uptake and Apoptotic Induction of Gemcitabine-Loaded Pegylated Unilamellar Liposomes
Anaplastic thyroid carcinoma is one of the most aggressive and lethal solid carcinomas affecting humans. A major limit of the chemotherapeutic agents is represented by their low th...
Ameliorative Role of Grape Seed Extract (Vitis Vinifera) on Gemcitabine- Induced Testicular Damage in Rabbits
Ameliorative Role of Grape Seed Extract (Vitis Vinifera) on Gemcitabine- Induced Testicular Damage in Rabbits
Spermatogenesis is a highly conserved and regulated process and it is sensitive to fluctuations in the physical and chemical environment. Gemcitabine is a novel antimetabolic antic...
Abstract 1828: Development and evaluation of novel gemcitabine analog for the treatment of pancreatic cancer
Abstract 1828: Development and evaluation of novel gemcitabine analog for the treatment of pancreatic cancer
Abstract
Purpose: Gemcitabine acts against pancreatic cancer and a wide range of solid tumors and it is known to be rapidly deaminated or metabolized in the blood to...

